ARQT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARQT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). Arcutis Biotherapeutics's Average Total Inventories for the three months ended in Sep. 2024 was $13.9 Mil. Arcutis Biotherapeutics's Cost of Goods Sold for the three months ended in Sep. 2024 was $5.5 Mil. Hence, Arcutis Biotherapeutics's Days Inventory for the three months ended in Sep. 2024 was 231.28.
The historical rank and industry rank for Arcutis Biotherapeutics's Days Inventory or its related term are showing as below:
During the past 7 years, Arcutis Biotherapeutics's highest Days Inventory was 3637.41. The lowest was 344.03. And the median was 2196.52.
Arcutis Biotherapeutics's Days Inventory declined from Sep. 2023 (941.33) to Sep. 2024 (231.28).
Inventory Turnover measures how fast the company turns over its inventory within a year. Arcutis Biotherapeutics's Inventory Turnover for the three months ended in Sep. 2024 was 0.39.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Arcutis Biotherapeutics's Inventory-to-Revenue for the three months ended in Sep. 2024 was 0.31.
The historical data trend for Arcutis Biotherapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcutis Biotherapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Days Inventory | Get a 7-Day Free Trial | - | - | - | 3,637.41 | 755.62 |
Arcutis Biotherapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Days Inventory | Get a 7-Day Free Trial | 941.33 | 549.43 | 369.67 | 357.29 | 231.28 |
For the Biotechnology subindustry, Arcutis Biotherapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Arcutis Biotherapeutics's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Arcutis Biotherapeutics's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as
Days Inventory (A: Dec. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2023 ) | * | Days in Period |
= | ( (7.514 | + | 13.134) | / | 2 ) | / | 4.987 | * | 365 |
= | 10.324 | / | 4.987 | * | 365 | ||||
= | 755.62 |
Arcutis Biotherapeutics's Days Inventory for the quarter that ended in Sep. 2024 is calculated as:
Days Inventory (Q: Sep. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Jun. 2024 ) | + | Total Inventories (Q: Sep. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Sep. 2024 ) | * | Days in Period |
= | ( (13.88 | + | 14.015) | / | 2 ) | / | 5.503 | * | 365 / 4 |
= | 13.9475 | / | 5.503 | * | 365 / 4 | ||||
= | 231.28 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcutis Biotherapeutics (NAS:ARQT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Arcutis Biotherapeutics's Inventory Turnover for the three months ended in Sep. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 5.503 | / | 13.9475 | |
= | 0.39 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Arcutis Biotherapeutics's Inventory to Revenue for the three months ended in Sep. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 13.9475 | / | 44.755 | |
= | 0.31 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of Arcutis Biotherapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Howard G. Welgus | director | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Larry Todd Edwards | officer: Chief Commercial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Todd Franklin Watanabe | director, officer: President and CEO | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Masaru Matsuda | officer: SVP and General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Patrick Burnett | officer: See Remarks | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Terrie Curran | director | C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Matthew Richard Moore | officer: SVP and Chief Business Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Patrick J Heron | director, 10 percent owner | 550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301 |
Frazier Life Sciences Viii, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Scott L Burrows | officer: Chief Financial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Patricia A. Turney | officer: Senior VP, Manufacturing | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
David W Osborne | officer: Chief Technical Officer | |
Kenneth A. Lock | officer: Chief Commercial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Neha Krishnamohan | director | 12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By GuruFocus News • 11-05-2024
By GuruFocus News • 11-06-2024
By Marketwired • 08-02-2024
By GuruFocus Research • 08-15-2024
By GuruFocus News • 11-07-2024
By Marketwired • 08-22-2024
By GuruFocus News • 11-14-2024
By GlobeNewswire • 08-15-2024
By GuruFocus News • 11-14-2024
By Marketwired • 10-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.